Cargando…

Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy

BACKGROUND: With the lack of real-world evidence, the challenge for drug reimbursement policy decision makers is to understand medication adherence behavior among users of novel oral anticoagulants (NOACs) and its effect on overall cost savings. No study has examined and quantified the burden of cos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Deshpande, Chinmay G., Kogut, Stephen, Willey, Cynthia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387835/ https://www.ncbi.nlm.nih.gov/pubmed/29694285 http://dx.doi.org/10.18553/jmcp.2018.24.5.430

Ejemplares similares

PHARMACY DEDUCTIBLES CAN COMPLICATE THE RELATIONSHIP BETWEEN MEASURES OF PATIENT COST SHARING AND MEDICATION ADHERENCE
por: Kogut, Stephen J, et al.
Publicado: (2023)

Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Medication adherence in Fabry patients treated with migalastat: Real world experience
por: Riccio, Eleonora, et al.
Publicado: (2023)

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
por: Anghel, Larisa, et al.
Publicado: (2020)

Direct oral anticoagulants: patient reported adherence and minor bleedings
por: Hayat, Amina, et al.
Publicado: (2023)

Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: a retrospective cohort study
por: Tanizawa, Kimihiko, et al.
Publicado: (2022)

Patient characteristics, adherence, and costs of oral anticoagulation therapy in non-valvular atrial fibrillation using the Dubai Real-World Claims Database
por: El Kadri, Moutaz, et al.
Publicado: (2021)

Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants
por: Luger, Sebastian, et al.
Publicado: (2015)

Real-world utilization of top-down and step-up therapy and initial costs in Crohn disease
por: Shah, Kanya K, et al.
Publicado: (2022)

Patient-specific and healthcare real-world costs of atrial fibrillation in individuals treated with direct oral anticoagulant agents or warfarin
por: Pyykönen, Mikko, et al.
Publicado: (2021)

Deceptive Adherence to Anticoagulation in Secondary Stroke Prevention
por: Vibo, Riina, et al.
Publicado: (2022)

Management of bleeding in patients treated with direct oral anticoagulants
por: Levi, Marcel
Publicado: (2016)

Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE
por: Kolonics-Farkas, Abigél M., et al.
Publicado: (2020)

Costs of medical care for mesothelioma
por: Borrelli, Eric, et al.
Publicado: (2019)

Real-World Data on Bleeding Patterns of Hemophilia A Patients Treated with Emicizumab
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2021)

Cost‐effectiveness of an adherence‐enhancing intervention for gout based on real‐world data
por: Lin, Lydia Wenxin, et al.
Publicado: (2018)

All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants
por: Deitelzweig, Steve, et al.
Publicado: (2018)

Performance of the ABC-bleeding risk score for assessing major bleeding risk in Chinese patients with atrial fibrillation on oral anticoagulation therapy: A real-world study
por: Wang, Yu-Feng, et al.
Publicado: (2022)

To Anticoagulate or Not: Acute Stroke in a COVID-19 Patient With Gastrointestinal Bleed
por: George, Justin, et al.
Publicado: (2020)

The risk of stroke/systemic embolism and major bleeding in Asian patients with non-valvular atrial fibrillation treated with non-vitamin K oral anticoagulants compared to warfarin: Results from a real-world data analysis
por: Bang, Oh Young, et al.
Publicado: (2020)

Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England
por: Bakhai, Ameet, et al.
Publicado: (2020)

Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation
por: Tiili, Paula, et al.
Publicado: (2021)

Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2019)

Estimating Adherence Based on Prescription or Dispensation Information: Impact on Thresholds and Outcomes. A Real-World Study With Atrial Fibrillation Patients Treated With Oral Anticoagulants in Spain
por: Hurtado-Navarro, Isabel, et al.
Publicado: (2018)

The use and adherence of oral anticoagulants in Primary Health Care in Catalunya, Spain: A real-world data cohort study
por: Giner-Soriano, Maria, et al.
Publicado: (2020)

Medication adherence, medical record accuracy, and medication exposure in real-world patients using comprehensive medication monitoring
por: Ryan, Timothy P., et al.
Publicado: (2017)

Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention
por: Habert, Jeffrey Steven
Publicado: (2016)

Direct Medical Cost of Stroke and the Cost-Effectiveness of Direct Oral Anticoagulants in Atrial Fibrillation-Related Stroke: A Cross-Sectional Study
por: Azahar, Siti Norain, et al.
Publicado: (2022)

Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals
por: Refaai, Majed A., et al.
Publicado: (2023)

Correction: Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings
por: de Jong, Lisa A., et al.
Publicado: (2022)

Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
por: Pham, Phuong N., et al.
Publicado: (2019)

Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis
por: Rodríguez-Bernal, Clara L, et al.
Publicado: (2018)

Direct Healthcare Costs by Level of Adherence of a Real-World Population of Statin Users in Italy
por: Degli Esposti, Luca, et al.
Publicado: (2022)

Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy
por: Moccia, Marcello, et al.
Publicado: (2022)

Decision of Anticoagulation in Nonvalvular Atrial Fibrillation in the Real World in the Non-Antivitamin K Anticoagulants Era
por: Gheorghe, Gabriela Silvia, et al.
Publicado: (2022)

The Impact of Agitation in Dementia on Caregivers: A Real-World Survey
por: Schein, Jeff, et al.
Publicado: (2022)

Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke Risks
por: Deitelzweig, Steve, et al.
Publicado: (2013)

Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants
por: Ording, Anne Gulbech, et al.
Publicado: (2021)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6a0ljqtmst91mtijirph5verk6